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Background: Pulmonary coagulopathy is a hallmark of lung injury following inhalation trauma. Locally applied heparin
attenuates lung injury in animal models of smoke inhalation. Whether local treatment with heparin benefits patients with
inhalation trauma is uncertain. The present trial aims at comparing a strategy using frequent nebulizations of heparin
with standard care in intubated and ventilated burn patients with bronchoscopically confirmed inhalation trauma.
Methods: The Randomized Controlled Trial Investigating the Efficacy and Safety of Nebulized HEParin versus Placebo
in BURN Patients with Inhalation Trauma (HEPBURN) is an international multi-center, double-blind, placebo-controlled,
two-arm study. One hundred and sixteen intubated and ventilated burn patients with confirmed inhalation trauma are
randomized to nebulizations of heparin (the nebulized heparin strategy) or nebulizations of normal saline (the control
strategy) every four hours for 14 days or until extubation, whichever comes first. The primary endpoint is the number
of ventilator-free days, defined as days alive and breathing without assistance during the first 28 days, if the period of
unassisted breathing lasts for at least 24 consecutive hours.
Discussion: As far as the authors know, HEPBURN is the first randomized, placebo-controlled trial, powered to
investigate whether local treatment with heparin shortens duration of ventilation of intubated and ventilated burn
patients with inhalation trauma.
Trial registration: NCT01773083 (www.clinicaltrials.gov), registered on 16 January 2013.
Recruiting. Randomisation commenced on 1 January 2014.
Keywords: Inhalation trauma, Pulmonary coagulopathy, Nebulization, Heparin, Mechanical ventilationBackground
Inhalation trauma adds to the morbidity and mortality
of burn patients [1,2]. Indeed, up to one third of burn
patients require hospitalization due to inhalation trauma
and a substantial percentage of these patients develop
respiratory insufficiency. Moreover, approximately one* Correspondence: g.j.glas@amc.uva.nl
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reproduction in any medium, provided the orthird of burn patients with inhalation trauma eventually
die, markedly more than burn patients without pulmon-
ary involvement.
The underlying pathophysiology of inhalation trauma
is only partly understood. Injury is thought to be at
least the result of heat exposure to the airway mucosa
or inhalation of noxious particles or toxic gases [3]. In-
jury of airway mucosa could induce an inflammatory re-
sponse resulting in vascular leakage and pulmonary
edema [4]. Pulmonary cast-formation could certainly
play a role, since one study of burn patients shows dis-
turbed alveolar fibrin turnover [5], and several preclinical. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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ation [6-9].
At present, therapy for inhalation trauma is merely
supportive [10]. Animal models of smoke injury [6,7,9]
and clinical trials of burn patients with inhalation
trauma suggest that local treatment with heparin has
beneficial effects [11,12]. The objective of the present
trial is to determine the clinical efficacy and safety of
frequent nebulizations of heparin in burn patients with
inhalation trauma. Furthermore, the present trial investi-
gates local effects of heparin on pulmonary coagulation
and inflammation.Methods
Design
The ‘Randomized Controlled Trial Investigating the Effi-
cacy and Safety of Nebulized HEParin versus Placebo in
BURN Patients with Inhalation Trauma’ (HEPBURN) is
an international multi-center, double-blind, placebo-
controlled, two-arm study. The trial is conducted in
accordance with the declaration of Helsinki [13]. The In-
stitutional Review Board of the Academic Medical Cen-
ter, Amsterdam, the Netherlands, approved the trial
protocol. The trial is registered at www.clinicaltrials.gov
(NCT01773083). Patients or their legal representative
have to give written informed consent before any study-
related procedure is performed.Figure 1 CONSORT diagram of HEPBURN. *Until successful liberation fro
**For the maximum duration of 28 days.CONSORT diagram
The CONSORT [14] diagram of HEPBURN study is pre-
sented in Figure 1. Consecutive burn patients with sus-
pected inhalation trauma are screened. Demographic
data and data on the extent of injury are registered re-
gardless of meeting enrollment criteria. If excluded from
participation, the reason(s) for exclusion are registered.
For screening of inhalation trauma, a clinical [15] and a
bronchoscopic [16] scoring system are used (Table 1).
Setting
HEPBURN is performed in three centers specialized in
care of burn patients in the Netherlands (Red Cross
Hospital, Beverwijk; Martini Hospital, Groningen; Maasstad
Hospital, Rotterdam) and three specialized centers in
Belgium (University Hospital Gasthuisberg - Leuven;
Ziekenhuis Netwerk Antwerpen (ZNA) - Hospital Net-
work Antwerp; Ghent University Hospital, Ghent).
Study population
Intubated and ventilated burn patients, > 18 years of age
with bronchoscopically confirmed inhalation trauma are
eligible for participation. Notably, intubated and venti-
lated patients without skin burns, but with bronchosco-
pically confirmed inhalation trauma, are also eligible for
participation in HEPBURN.
Patients are excluded if they are not enrolled within the
first 36 hours after trauma, if intubated and ventilated form mechanical ventilation or for the maximum duration of 14 days.
Table 1 Clinical scoring and grading of inhalation trauma
A. Clinical scoring system [15]
1 History of being trapped in a house or industrial fire in an enclosed
space
2 Production of carbonaceous sputum
3 Peri-oral facial burns affecting nose, lips, mouth, or throat
4 Altered level of consciousness at any time after the incident
and including confusion
5 Symptoms of respiratory distress, including a sense of suffocation,
choking, breathlessness, and wheezing or discomfort affecting the
eyes or throat, indicating irritation of the mucous membranes
6 Signs of respiratory distress, including stertorous, labored breathing,
and tachypnea or auscultatory abnormalities, including crepitations
or rhonchi
7 Hoarseness or loss of voice
B. Severity of inhalation trauma [16]
0 No injury Absence of carbonaceous deposits, erythema,
edema, bronchorrhea, or obstruction
1 Mild injury Minor patchy areas of erythema or carbonaceous
deposits in proximal or distal bronchi
2 Moderate injury Moderate degree of erythema, carbonaceous
deposits, bronchorrhea or bronchial obstruction
3 Severe injury Severe inflammation with friability, copious
carbonaceous deposits, bronchorrhea
or obstruction
4 Massive injury Evidence of mucosal sloughing, necrosis or
endoluminal obliteration
A. Clinical scoring system [15]. One point is given for the presence of each
clinical factor considered to be suggestive of smoke inhalation to a total of
seven points; a score of greater than 2 is considered fulfilling the criteria for
unequivocal smoke inhalation. B. Severity of inhalation trauma based on
bronchoscopic findings.
Glas et al. Trials 2014, 15:91 Page 3 of 11
http://www.trialsjournal.com/content/15/1/91longer than 24 hours prior to trial enrollment, and if un-
likely to survive for more than 72 hours or have burns
covering > 60% of total body surface area (TBSA). Patients
are also excluded if the expected duration of intubation
and ventilation is less than 24 hours. Other exclusion cri-
teria are history of severe chronic obstructive pulmonary
disease (COPD) with (non-invasive) ventilation or oxygen
therapy at home or repeated systemic corticosteroid
therapy for acute exacerbations, witnessed or bronchosco-
pically proven aspiration, any history of pulmonary hemor-
rhage in the past three months, any history of clinically
important bleeding disorder, known allergy to heparin or
heparin-induced thrombocytopenia, and pregnancy or
breast feeding.
Randomization, blinding and intervention
Randomization is performed using ALEA® software
(TenALEA consortium, Amsterdam, the Netherlands)
and uses random blocks. Prior to randomization, pa-
tients are stratified for burn center and TBSA < 20%
versus TBSA ≥ 20%. Patients are identified by study ID-
numbers (randomization numbers) that are linked to the
assigned study medication (heparin or normal saline).The pharmacist at each study site has access to the con-
fidential file containing the randomization scheme,
which links ID-numbers to appropriate ampoules. Since
heparin and placebo are packed identically, they are pro-
vided with a temporary additional label ‘verum’ in case
of heparin, or ‘placebo’ in case of saline. Before dispens-
ing the medication to the ward, this additional label will
be removed by the pharmacy, after which the medication
is blinded for the study team. Nebulized volumes are
identical.
Patients are randomly assigned to nebulization of
study medication consisting of unfractionated sodium
heparin (Pfizer, Melbourne, Australia) or sodium chlor-
ide 0.9% (Pfizer, Melbourne, Australia), administered
every four hours (that is six times per day). For this, the
total volume of identically packed 5 mL ampoules
containing 25,000 IU of unfractionated heparin or
0.9% NaCl, is nebulized using an AeronebPro system
(Aerogen Inc, Sunnyvale, CA, USA), connected to the
ventilator circuit closest to the patient, but always in be-
tween the patient and the heat and moist exchanger if
used. To prevent potential damage from nebulized hep-
arin to the expiratory valve of the ventilator, a filter is
placed in the expiratory limb of the circuit. Each nebuli-
zation session lasts 15 minutes. Nebulization of study
medication is continued until tracheal extubation or
death, but for a maximum duration of 14 days.
Protocol drop-out
Nebulization of study medication can be discontinued
temporarily when heparin-induced thrombocytopenia
(HIT) is suspected. Nebulization of study medication is
definitely discontinued when HIT is confirmed. Further-
more, nebulization of study medication can be discontin-
ued temporarily in case of surgical procedures, clinically
relevant bleeding (mandating infusion of clotting factors,
fresh frozen plasma or platelet concentrates), activated
partial thromboplastin time of > 150 seconds and a plate-
let count of ≤ 10 × 109/L. Finally, study medication can be
discontinued temporarily with appearance of excessive
blood in sputum or lavage fluids. Timing of re-start is left
to the discretion of the attending physician, but it is
stressed to re-start study medication as soon as it is con-
sidered safe. In case of any life-threatening bleeding event,
protamine sulphate can be used as an antidotum to hep-
arin, at the discretion of the attending physician.
Concomitant medication
Intravenous or oral anticoagulant therapy, if indicated, is
allowed. Routine use of N-acetylcysteine or any other
mucolytic agent, either nebulized or directly installed
into the airways, is not allowed. They should only be
used when viscous mucus is considered problematic, at
the discretion of the attending physician.
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Attending physicians are advised to use lung-protective
ventilation strategies, including the use of lower tidal
volumes (≤ 6 mL/kg predicted body weight) or lower air-
way pressures (≤ 30 cmH2O). Levels of positive end-
expiratory pressure (PEEP) and inspired oxygen (FiO2)
are titrated on PaO2, preferably using a PEEP/FiO2 table,
and according to local guidelines. If spontaneous ventila-
tion is well tolerated, it is used from then till the end of
ventilation. Thereafter, weaning from ventilation is per-
formed by stepwise lowering of pressure-support level,
or by spontaneous breathing trials, according to local
guidelines. As soon as patients are ready to be weaned
from the ventilator, the pressure-support level is lowered
stepwise to 5 cmH2O. In case of spontaneous breathing
trials, the patient’s ability to breathe spontaneously is
verified for 30 minutes using a T-piece or continuous
positive airway pressure. Patients are assessed daily if
they are ready to be tracheally extubated. Extubation cri-
teria are as follows: patient is responsive and coopera-
tive, has an adequate oxygenation (saturation > 90%)
with PaO2/FiO2 of 150 mmHg or more and FiO2 of 40%
or less, is hemodynamically stable with no uncontrolled
arrhythmia, and has a rectal temperature > 36.0°C. At-
tending physicians are advised not to perform tracheoto-
mies in the first 14 days after inclusion. If a patient
meets extubation criteria, but remains intubated because
of planned surgeries requiring general anesthesia, this is
reported.
Analgo-sedation and fluid management are according
to local guidelines. Analgo-sedation is achieved by con-
tinuous or bolus infusion of either fentanyl or morphine
in combination with a benzodiazepine or propofol, ti-
trated to individual needs. Procedure-related analgesia
and sedation are at the discretion of the attending phys-
ician. Sedation depth is measured on a daily basis, and is
used to titrate infusions of sedatives.
In general, patients are resuscitated using buffered
hypertonic or isotonic saline solutions, targeting a urine
output of 0.5 to 1.0 ml/kg/h. If necessary to maintain
serum albumin concentration > 15 g/L, human albumin
is administered. After the first 24 hours, fluid adminis-
tration is dictated by clinical needs.
Antibiotic prophylaxis and thromboprophylaxis are
applied in accordance to local guidelines. We chose to
allow the use of systemic or oral anticoagulants. Al-
though we expect that the use of (intravenous) anti-
coagulant agents and prophylactic antibiotics will be
similar in both groups, we will record the use of these
agents.
Follow-up
On the day of ICU admission, demographic and baseline
data, as well as data on disease severity and extent ofburn injury are collected. Data collection includes: gen-
der, age, height, weight, functional status (independent,
partially dependent or totally dependent), cardiac status
(heart failure, according to the New York Heart Associ-
ation (NYHA) [17], acute coronary syndrome or persist-
ent ventricular tachyarrhythmia), alcohol status (in the
past two weeks: 0 to 2 drinks/day, or more than 2
drinks/day), smoking status (in the past three months:
never, former, or current). Data collection on relevant
medical history include: COPD for which inhalation
therapy or oral steroids are used, respiratory infection in
the last month (upper or lower), history of active cancer,
weight of loss more than 10% in the last six months, his-
tory of diabetes mellitus, chronic kidney disease, liver
failure (Child-Pugh classification) [18], acquired im-
munodeficiency syndrome and use of relevant medica-
tions (including oral anti-diabetics, antibiotics in the last
three months, statins, and corticosteroids). Regarding
extent of burn injury, collected data include TBSA, par-
tial or full thickness burn, Belgian Outcome in Burn In-
jury Study Group Index [19] and the Abbreviated Burn
Severity Index (16).
Data on standard of care and clinical outcome vari-
ables (described below) are collected on a daily basis for
the maximum duration of 28 days, until first discharge
from ICU or death (whichever comes first). Data on
length of stay in ICU and - hospital, mortality in ICU
and hospital, and re-admissions to ICU are assessed on
days 28 and 90 (Table 2).
The following variables are collected daily: ventilator
freedom (described below), requirement for non-invasive
mechanical ventilation (if yes: indication and duration
per day), Oxygenation Index (OI) [20], Sequential Organ
Failure Assessment (SOFA) scores [21], Lung Injury
Score (LIS, based on chest X-ray findings, PaO2/FiO2,
PEEP level and respiratory compliance) [22], presence of
ventilator-associated pneumonia (VAP), presence of
acute respiratory distress syndrome (ARDS) [23], num-
ber of bronchoscopy-guided cleaning attempts per day
to clean the larger airways, and use of relevant medica-
tions (including antimicrobial agents, immunosuppres-
sive agents, and any anticoagulant agent).
The following laboratory data are collected daily: gly-
cemia, urea, creatinine, aspartate aminotransferase, alanine
aminotransferase, bilirubin, hemoglobin (Hb), platelets,
prothrombin time (PT), aPTT, white blood cells count, al-
bumin, and arterial blood gas analysis.
Typical ICU-related therapy variables to collect daily
include: ventilation variables, need for lung rescue ther-
apy (such as prone ventilation, extracorporeal membrane
oxygenation or oscillator), analgo-sedation variables (in-
cluding sedations scores, using for example, the Richmond
Agitation Sedation Scale (RASS) [24], and delirium scores,
using for example, the Confusion Assessment Method
Table 2 Time schedule of study procedures
Day of admission
(day 1)
Every dayb/c Days 1, 3, 5, 7, 9,
11 and 13c
Day of hospital
discharge
Day 28 Day 90
Screening and randomization
screeninga X
demographic data X
inclusion criteria X
exclusion criteria X
informed consent X
randomization X
Before start study medication
blood sampling X
non directed broncho-alveolar lavage sampling X
Clinical procedures
chest X-ray X
nebulization of study medicationc,d X
blood samplingc X
non-directed broncho-alveolar lavage samplingc X
Clinical data collection
%TBSA X
SAPS II X
Karnofsky score X
ABSI X
SOFA score X
LIS/OI X
ventilatory settings X
relevant medicationse X
sedation X
fluid balance X
Other data collection
adverse event X
use of blood products X
use of protamine X
use of n-acetylcysteine X
use of vasopressorsf X
bronchoscopyg X
pneumonia (VAP) X
date of hospital discharge X
Survival, if not: X X X
date of death
cause of death
aOf all patients with suspected inhalation injury.
bFor the maximum duration of 28 days.
cFor the maximum duration of 14 days or until the patient is successfully weaned from mechanical ventilation.
dIf temporarily or definitely discontinued, reason should be registered.
eSuch as antibiotics, immunosuppressives, systemic anticoagulants.
fSuch as dopamine, dobutamine, norepinephrine, or epinephrine.
gTo remove foreign particles and accumulated secretions.
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point score, cumulative dose of sedatives and analgesics
(including fentanyl, morphine, midazolam, and propofol),
and fluid resuscitation variables including cumulative fluid
balance [26], amount and type of infused fluids (for ex-
ample, crystalloids, colloids and albumin), and daily
amount of enteral/parenteral nutrition [27]. After the first
14 days, data on tracheotomies are collected.
Any surgical procedure, the amount of blood loss,
presence of serious bleedings (defined as any clinically
important bleeding from the lung (prompting bronchos-
copy) or any clinically important bleeding requiring sur-
gery or transfusion of clotting factors or blood products
(red cells, platelets, plasma) is reported. Type and num-
ber of units transfused are specified as well as reasons to
(temporarily) discontinue study medication, as described
above, are reported as well.
Study endpoints
The primary endpoint - is the number of ventilator-free
days, defined as the number of days alive and breathing
without the assistance of a ventilator during the first
28 days. Thus, a patient must be free of ventilation for
24 hours to have one ventilator-free day. If, after suc-
cessful extubation the patient requires re-intubation and
ventilation due to a surgical procedure, this episode will
not count as a ventilator day. However, if after surgery,
ventilation is prolonged due to respiratory insufficiency,
the day(s) will be counted as ventilator days.
Secondary endpoints - are subdivided into clinical and
laboratory outcome variables and safety variables. Clin-
ical outcome variables include: (a) length of stay (ICU
and hospital); (b) mortality (28- and 90-day); (c) mortal-
ity (ICU and hospital); (d) daily LIS; (e) daily OI; (f ) daily
SOFA scores; (g) cumulative dosages of sedatives; (h) in-
cidence of VAP; (i) total number of bronchoscopy-guided
cleanings of the larger airway. Laboratory outcome vari-
ables include: (a) levels of markers of coagulation and fi-
brinolysis in blood and lung lavage fluid, including but not
limited to tissue factor, activated factor VII, antithrombin,
thrombin-antithrombin complexes, activated protein C,
plasminogen activator activity, tissue plasminogen activa-
tor, urokinase plasminogen activator, plasminogen activa-
tor inhibitor 1, fibrin degradation products and plasma
levels of heparin; (b) levels of markers of inflammation in
blood and lung lavage fluid, including but not limited to
IL-1beta, IL-6, IL-8, IL-10, TNF-alpha, growth factors and
markers of complement activation; and (c) biological
markers of lung injury in blood and lung lavage fluid, in-
cluding but not restricted to total protein, albumin and
IgM, Clara Cell 16 protein and soluble receptor for ad-
vanced glycation endproducts. Safety variables include (a)
occurrence of relevant bleedings - requiring surgery,
requiring transfusion of clotting factors, requiringtransfusion of blood products (red cells or platelets or
plasma), any clinically important bleeding from the lung
(prompting bronchoscopy); (b) any other transfusion of
blood products - red cells or platelets or plasma; (c) con-
firmed HIT; and (d) prolonged activated partial thrombo-
plastin time (aPTT > 150 seconds).
Collection of blood samples and lung lavage fluid
In selected centers, blood is drawn through the existing
arterial line and processed immediately. A total volume
of 20 mL is drawn every other day for a maximum
period of 14 days, and always before performing the lung
lavage. A non-directed lung lavage is performed every
other day for a maximum period of 14 days or less if the
patients are successfully weaned from mechanical venti-
lation. Lung lavage is performed as described before
[28]. In brief, 20 ml sterile 0.9% saline is instilled via a
standard 50 cm 14 gauge tracheal suction catheter. The
distal end of the catheter is introduced via the endo-
tracheal tube and advanced until resistance is encoun-
tered. Immediately after instillation of the saline solution
over 4 to 5 seconds, fluid is aspirated before withdrawal
of the catheter. Plasma and lung lavage fluid are centri-
fuged and stored at −80°C until assays (described above)
are performed.
Statistical considerations
Sample size calculation - in a previous trial testing the
efficacy of nebulized heparin, critically ill patients requir-
ing ventilation for at least 48 hours showed a reduction
of 4.6 days of ventilation (mean (SD) 22.6 (4.0) versus
mean (SD) 18.0 (7.1)) [29]. We conservatively estimate
that the improvement in burn patients with inhalation
trauma is less than in a heterogeneous group of critically
ill non-burn patients. We consider a reduction of three
days of ventilation clinically relevant. We require 58 pa-
tients per treatment arm to observe a difference in the
number of ventilator-free days at day 28 with (α < 0.05 at
80% power). Although burn patients with inhalation
trauma usually have fewer ventilator-free days than crit-
ically ill non-burn patients, the standard deviation ap-
pears to be similar between burn injury patients [30]
and critically ill patients in general [31], indicating that
the sample size of 58 per arm for a total of 116 is suffi-
cient to observe an improvement of three ventilator-free
days (nQuery Advisor Software version 7.0, Statistical
Solutions Ltd, Cork, Ireland).
Stratification - considering the fact that TBSA is asso-
ciated with prolonged duration of ventilation [32], we
want to avoid an uneven distribution of the severity of
burns between study groups. Therefore, patients are
stratified based on TBSA (≥ 20% versus < 20%). Provided
that this stratification will only be used to ensure an
equal distribution, and stratification is based on the
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study.
Interim analysis - blind interim analysis for safety is
performed after 58 patients are successfully included
and reached the endpoint. Suspected unexpected serious
adverse events (SUSARs) and serious adverse events
(SAEs) (any death; all serious bleedings requiring sur-
gery, transfusion of clotting factors or blood products;
any clinically important bleeding from the lung; require-
ment of transfusion of blood products; and confirmed
heparin-induced thrombocytopenia) that are possibly re-
lated to study medication will be compared using the
Chi-square test. If the data safety monitoring board
(DSMB) (see below) has concern regarding the incidence
of serious adverse events, it can request unblinded data.
The investigators will remain blinded for the groups
until the study is completed. If complications occur sig-
nificantly more often in the intervention group (P ≤
0.05), the study is terminated due to harm.
Statistical analysis
Patient characteristics will be compared and described
by appropriate statistics. Data will be analyzed on an
intention-to-treat basis. Normally distributed variables
will be expressed by their mean and standard deviation
and non-normally distributed variables will be expressed
by their medians and 95% confidence levels. Categorical
variables will be expressed as N (%). To test for normal-
ity, a D’Agostino and Pearson omnibus test will be per-
formed [33]. Differences between groups will be tested
by Student’s t-test for normally distributed data and
Mann–Whitney U-test for not normally distributed data.
Categorical variables will be compared with the Chi-
square test or Fisher’s exact tests or when appropriate as
relative risks. The difference of the primary effect vari-
ables will be analyzed using the Mann–Whitney U-test.
The rate of freedom from ventilation will be analyzed ac-
cording to the Kaplan-Meier method [34] and the results
will be compared with the log-rank test hazard ratio’s
are reported with 95% confidence limits. To take into ac-
count the stratification factors, we will perform an ad-
justed analysis. TBSA levels are group level data that will
be included as a second level covariate in a multilevel
linear regression model to assess the adjusted effect of
our randomized treatment. Also the treatment effect on
coagulation markers is investigated. Because they are
clustered within each patient (repeated measurements)
we will also use a multilevel model to evaluate the influ-
ence of the cluster effect on the model fit, that is we will
compare the model fit without a second level (the pa-
tient) with the model fit that includes the patient as a
second level. When appropriate, statistical uncertainty
will be expressed by the 95% confidence levels. Statistical
significance is considered to be at a P of 0.05. Analysiswill be performed with SPSS version 18.1 (SPSS Inc.,
Chicago, IL, USA).
Study organization
The Steering Committee is composed of the principal
investigators of the participating centers who contribute
to the design and revisions of the study protocol. The
national coordinators in the Netherlands and in Belgium
ensure that all local necessary ethical and regulatory ap-
provals are obtained before start of patient inclusion. In
individual participating centers, local coordinators pro-
vide scientific and structural leadership in their center.
They guarantee the integrity of data collection and en-
sure timely completion of case report forms (CRFs). The
trial coordinator trains and monitors the participating
centers to ensure the study is conducted according to
ICH-GCP guidelines [35], guarantees the integrity of
data collection and ensures timely completion of CRFs.
An independent monitor performs study monitoring.
The independent DSMB is composed of four independ-
ent persons (Prof. Dr. Marcelo Gama de Abreu, Prof. Dr.
Samir Jaber, Prof. Dr. Paolo Pelosi, and Prof. Dr. Antonio
Artigas Raventós). The DSMB reviews the overall status
of the program (number of patients enrolled overall and
in each center, adherence to the protocol overall and by
each center) and receives an interim analysis on safety
(described below). The DSMB will meet by conference
calls. The first meeting is scheduled after 15 patients are
enrolled. Subsequent to this meeting, the DSMB will
meet every six months.
All adverse events reported are sent to the DSMB for
review in a blinded fashion. All (possibly) related and
unrelated severe adverse events (SAEs) and suspected
unexpected serious adverse reactions (SUSARs) will be
sent to the DSMB within 24 hours after being received
by the coordinating center. Non-serious study-related
adverse events will be sent every week. Non-serious
study-unrelated adverse events are recorded in an over-
view list (line-listing), submitted once every half year.
If the DSMB has concern regarding the incidence of
SAEs, the DSMB can request and will be supplied with
unblinded data. The investigators will never see these
data. When complications occur significantly more often
in the intervention group (P ≤ 0.05), terminating the
study due to harm will be considered.
Discussion
Pulmonary coagulopathy and subsequent fibrin depos-
ition is an important feature of a wide variety of inflam-
matory lung conditions. Indeed, pulmonary disturbances
in coagulation and fibrinolysis have been described with
remarkable uniformity with the acute respiratory dis-
tress syndrome (ARDS) [36-38], pneumonia [36,39], and
ventilator-associated lung injury [40]. In addition, pulmonary
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tory conditions of the lung, such as asthma, [41], COPD
[42], idiopathic pulmonary fibrosis [43] and interstitial
lung diseases [44,45].
More recently we showed that local coagulopathy is
also a feature of inhalation trauma [5]. The presence of
airway obstructive casts composed of mucus, epithelial
and inflammatory cells and fibrin, is considered a major
factor that contribute to pulmonary dysfunction in pa-
tients with inhalational trauma [46]. In patients who
need ventilatory support, overdistention of aerated lung
parts may occur while other parts remain atelectatic due
to airways obstructed by casts [11,46].
Coagulation and inflammation are intricately related
processes that considerably affect each other [47]. There
are several pathways by which procoagulant and inflam-
matory mechanisms can induce or worsen lung injury
[48]. Activation of coagulation is both a consequence
and a contributor to ongoing lung injury [49]. Given the
procoagulant shift in the pulmonary compartment in pa-
tients with inhalation trauma [5], pulmonary coagulopa-
thy could be considered as a potential therapeutic target.
Heparin is widely used as an anticoagulant and exerts
its effect through its ability to increase the activity of an-
tithrombin III, thereby reducing thrombin generation
[50]. Notably, the biological action of heparin extends
beyond its anticoagulant activity [29]. First, heparin has
been shown to inhibit leukocyte activation, which may
have an impact on pulmonary inflammation [31]. Second,
heparin inhibits fibroblast proliferation and collagen de-
position [51] and may thus affect tissue remodeling. Third,
heparin has been shown to reduce adhesion of bacteria
and viruses, which may have an impact on infectious com-
plications in mechanically ventilated patients [52]. Finally,
heparin may interfere with the recruitment of neutrophils
towards inflammatory sites [53-55].
Beneficial effects of heparin nebulization alone or in
combination with other agents are demonstrated in sev-
eral preclinical models of inhalation trauma [6,7,9,11,12].
In an ovine model of smoke inhalation injury followed
by sepsis after Pseudomonas aeruginosa instillation in
the lungs, nebulized heparin results in improved oxygen-
ation and reduces airway obstruction by casts [9]. Bene-
ficial effects are also seen with systemically administered
heparin, but only at relatively high dosages [56].
Two retrospective clinical studies with nebulized hep-
arin in patients with smoke inhalation injury at least
suggest that local heparin treatment could have benefi-
cial effects [11,12]. It is uncertain whether this treatment
truly benefits patients with inhalation trauma, however.
First, the two clinical studies so far tested the efficacy of
heparin in combination with mucolytic agents and bron-
chodilators. Second, these trials have some methodo-
logical problems, since they were single-center trialsusing historical controls. Third, it is uncertain whether
local treatment with heparin is safe [11,12,57]. As far as
the authors know, HEPBURN is the first double-blind,
randomized, placebo-controlled trial of nebulized hep-
arin in burn patients with inhalation trauma, focusing
both on clinical efficacy and safety. In addition to clinical
outcomes, HEPBURN is designed to determine whether
nebulized heparin reduces pulmonary coagulopathy and
inflammation. In a model of lung injury, the LPS-
induced procoagulant state in the lungs could be re-
versed through aerosol delivery of anticoagulants [58]. In
this model, heparin also reduced inflammatory cell num-
bers in BAL fluid, suggesting that nebulized heparin
could also impact pulmonary inflammation. It remains
uncertain, however, whether beneficial effects of nebu-
lized heparin depend on possible effects on pulmonary
inflammation, or solely on effects on pulmonary coagu-
lation. To gain more insight into this, we will compare
patients who receive heparin with patients who receive
placebo with respect to several inflammation and coagu-
lation variables in lung lavage fluid. This may enable us
to identify a possible mechanism by which nebulized
heparin affects the course of inhalation injury in burn
patients.
Studies in healthy volunteers demonstrate that ap-
proximately 8% of nebulized heparin reaches the lower
respiratory tract, of which 40% remains present 24 hours
after inhalation [59]. The dose of nebulized heparin (ap-
plied as a single dose) that results in measurable in-
creases in plasma aPTT is 150,000 IU and the half-life of
the inhaled heparin is estimated to be 28 hours [60].
Since the type of nebulizer could affect the percentage of
dose reaching the lower respiratory tract, we use the
same nebulizer type as in previous clinical trials of nebu-
lized heparin in critically ill patients [29,61]. In this trial,
both dosing and duration of local heparin therapy are
different from the two retrospective clinical studies of
nebulized heparin in burn patients [11,12]. We based
the dose, frequency and duration of heparin nebulization
on a previous trial of critically ill patients, in which hep-
arin nebulization was safe and associated with an in-
crease in the number of ventilator-free days [29].
A major concern regarding safety could be the occur-
rence of serious bleedings. It might be argued that, due
to endothelial injury and the increased vascular perme-
ability resulting from the inhalational injury, the sys-
temic impact of nebulized heparin and the risk of
pulmonary bleedings might be higher in burn patients
with inhalation injury when compared to critically ill pa-
tients without inhalation injury. However, two preclinical
studies of burn and smoke inhalation injury models re-
ported that heparin nebulization did not affect the sys-
temic clotting time [6,9]. To date, data on safety of local
heparin treatment in burn patients with inhalation
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occur significantly more often in one arm.
We chose the number of ventilator-free days at day 28
as the primary endpoint of this trial, a clinically relevant
outcome parameter in critically ill patients. The effect of
heparin may vary depending on the severity of injury [6].
However, the sample size of this trial does not allow sub-
group analyses, for example, the evaluation as to what
extent the efficacy of heparin depends on the severity of
burn injuries.
To increase uniformity between participating centers,
mechanical ventilation and weaning are performed ac-
cording to our study protocol. Attending physicians are
also advised not to use a tracheotomy in the first 14 days
after inclusion and routine use of mucolytic agents is
not allowed. In addition, data on applied care and on the
use of relevant concomitant medications such as antico-
agulants and mucolytics are collected. Nevertheless,
differences in care practices amongst the different par-
ticipating centers may be considered as a confounding
factor in our study. On the other hand, it may also indi-
cate whether nebulized heparin is applicable even when
there are (subtle) differences in standardized care.
In conclusion, as far as the authors know, the HEP-
BURN study is the first prospective double-blind, ran-
domized, placebo-controlled trial powered to test the
hypothesis whether nebulized heparin increases the
number of ventilator-free days in burn patients with in-
halation trauma, to evaluate the safety of this strategy,
and to investigate the local effects of heparin on pul-
monary coagulopathy and inflammation.
Trial status
Patient recruitment started in October 2013.
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